Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 2, 2006, Pages 183-188

  Yamashita, Tetsuro ^a,b   Ueda, Yuji ^a   Fuji, Nobuaki ^a   Itoh, Tsuyoshi ^a   Kurioka, Hideaki ^b   Shirasaka, Tetsuhiko ^c   Yamagishi, Hisakazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 fluorouracil; Gastric cancer; Immunosuppression; Potassium oxonate; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CONCANAVALIN A; FLUOROURACIL; INTERLEUKIN 2; OXONATE POTASSIUM; TEGAFUR; TS 1; UFT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE DEFICIENCY; LEUKOCYTE COUNT; MALE; MESENTERY LYMPH NODE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALS; DRUG COMBINATIONS; ENZYME INHIBITORS; FLUOROURACIL; IMMUNOPHENOTYPING; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; NEOPLASMS, EXPERIMENTAL; OXONIC ACID; PYRIDINES; RATS; TEGAFUR;

EID: 33646469073     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0150-0     Document Type: Article

References (31)

1. Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653
2. Heidelberger C, Danenberg PV, Moran RG (1983) Fluorinated pyrimidines and their nucreosides. Adv Enzymol Relat Areas Mol Biol 54:57
3. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996) Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602
4. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548
5. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203
6. Tatsumi K, Fukushima M, Shirasaka T, Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78:748
7. Ueda Y, Yamagishi H, Yamashita T, Itoh N, Itoi H, Shirasaka T, Ajani JA (2004) S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5′-DFUR: a case report with pharmacokinetic study. Jpn J Clin Oncol 34:282
8. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004
9. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000
10. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39:205
11. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715
12. Maehara Y (2003) S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6(Suppl 1):2
13. Yonemori K, Shimada Y, Goto A, Ura T, Arai T, Hamaguchi T, Muro K, Yamada Y, Shirao K (2004) Retrospective analysis of clinical results and predictors of response in chemo-naive patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy. Gastric Cancer 7:204
14. Koizumi W (2005) Available options in chemotherapy for advanced gastric cancer: the current developments in Japan. Expert Opin Pharmacother 6:225
15. Frei E (1972) Combination cancer therapy: presidential address. Cancer Res 32:2593
16. Duschinsky R, Pleven E, Heidelberger C (1957) The synthesis of 5-fluoropyrimidines. J Am Chem Soc 79:4559
17. Danenberg PV (1977) Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473:73
18. Santi DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13:471
19. Merluzzi VJ, Last-Barney K, Susskind BM, Faanes RB (1982) Recovery of humoral and cellular immunity by soluble mediators after 5-fluorouracil-induced immunosuppression. Clin Exp Immunol 50:318
20. Umeda Y, Sakamoto A, Nakamura J, Ishitsuka H, Yagi Y (1983) Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays. Cancer Immunol Immunother 15:78
21. Kiessling R, Petranyi G, Karre K, Jondal M, Tracey D, Wigzell H (1976) Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems. J Exp Med 143:772
22. Herberman RB, Holden HT (1978) Natural cell-mediated immunity. Adv Cancer Res 27:305
23. Balch CM, Tilden AB, Dougherty PA, Cloud GA (1983) Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg 198:192
24. Tartter PI, Steinberg B, Barron DM, Martinelli G (1987) The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 122:1264
25. Wu J, Lanier LL (2003) Natural killer cells and cancer. Adv Cancer Res 90:127
26. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Melloni E, Vitale M (2004) The response of human natural killer cells to interleukin-2. J Endocrinol Invest 27(6 Suppl):146
27. Yoshisue K, Hironaga K, Yamaguchi S, Yamamoto A, Nagayama S, Kawaguchi Y (2000) Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats. Cancer Chemother Pharmacol 46:51
28. Korenaga D, Honda M, Yasuda M, Inutsuka S, Nozoe T, Tashiro H (2002) Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats. Eur Surg Res 34:351
29. Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, Monden M (2003) Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil. Oncology 64:176
30. Ajani JA (1998) Chemotherapy for gastric carcinoma: new and old options. Oncology 12:44
31. Ajani JA, Takiuchi H (1999) Recent developments in oral chemotherapy options for gastric carcinoma. Drugs 58(Suppl 3):85